Neurobiology confirms psychopathology: On the antagonism of psychosis and obsessive-compulsive syndromes

Psychopathology

Volumn 41, Issue 5, 2008, Pages 279-285

  Zink, Mathias ^a,b   Englisch, Susanne ^a   Dressing, Harald ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

Author keywords

Antagonism; Comorbidity; Compulsions; Dopamine; Glutamate; Obsessions; Psychosis; Schizophrenia; Serotonin

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOMIPRAMINE; CLOZAPINE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR;

DOPAMINERGIC SYSTEM; DRUG POTENCY; EXTRAPYRAMIDAL SYNDROME; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; MENTAL DISEASE; NERVE CONDUCTION; NEUROANATOMY; NEUROBIOLOGY; NEUROTRANSMISSION; OBSESSIVE COMPULSIVE DISORDER; PROGNOSIS; PROLACTIN BLOOD LEVEL; PSYCHOSIS; REVIEW; SEROTONINERGIC SYSTEM; SEXUAL DYSFUNCTION; SIDE EFFECT;

BRAIN; DIAGNOSIS, DIFFERENTIAL; HUMANS; OBSESSIVE-COMPULSIVE DISORDER; PSYCHOTIC DISORDERS;

EID: 45949095026     PISSN: 02544962     EISSN: None     Source Type: Journal    
DOI: 10.1159/000141922     Document Type: Review

References (84)

1. Dowling FG, Pato MT, Pato CN: Comorbidity of obsessive-compulsive and psychotic symptoms: a review. Harvard Rev Psychiatry 1995;3:75-83.
2. Byerly M, Goodman W, Acholonu W, Bugno R, Rush AJ: Obsessive-compulsive symptoms in schizophrenia: frequency and clinical features. Schizophr Res 2005;76:309-316.
3. Öngür D, Goff DC: Obsessive-compulsive symptoms in schizophrenia: associated clinical features, cognitive function and medication status. Schizophr Res 2005;75:349-362.
4. Bottas A, Cooke RG, Richter MA: Comorbidity and pathophysiology of obsessive-compulsive disorder in schizophrenia: is there evidence for a schizo-obsessive subtype of schizophrenia? J Psychiatry Neurosci 2005;30:187-193.
5. Frommhold K: Obsessive-compulsive disorder and schizophrenia: a critical review. Fortschr Neurol Psychiatr 2006;74:32-48.
6. Poyurovsky M, Weizman A, Weizman R: Obsessive-compulsive disorder in schizophrenia: clinical characteristics and treatment. CNS Drugs 2004;18:989-1010.
7. Poyurovsky M, Koran LM: Obsessive-compulsive disorder (OCD) with schizotypy vs. schizophrenia with OCD: diagnostic dilemmas and therapeutic implications. J Psychiatr Res 2005;39:399-408.
8. Poyurovsky M, Kriss V, Weisman G, Faragian S, Kurs R, Schneidman M, et al: Comparison of clinical characteristics and comorbidity in schizophrenia patients with and without obsessive-compulsive disorder: schizophrenic and OC symptoms in schizophrenia. J Clin Psychiatry 2003;64:1300-1307.
9. Bürgy M: Psychopathology of obsessive-compulsive disorder: a phenomenological approach. Psychopathology 2005;38:291-300.
10. Bürgy M: Obsession in the strict sense: a helpful psychopathological phenomenon in the differential diagnosis between obsessive-compulsive disorder and schizophrenia. Psychopathology 2007;40:102-110.
11. Berrios GE: Obsessive-compulsive disorder: its conceptual history in France during the 19th century. Compr Psychiatry 1989;30:283-295.
12. Westphal K: Über Zwangsvorstellungen. Arch Psychiatr Nervenkr 1878;8:734-750.
13. Stengel E: A study on some clinical aspects of the relationship between obsessional neurosis and psychotic reaction types. J Ment Sci 1945;91:166-187.
14. Rosen I: The clinical significance of obsessions in schizophrenia. J Ment Sci 1957;103:773-785.
15. Sanders J, Whitty P, Murray D, Devitt P: Delusions or obsessions: the same only different? A case report. Psychopathology 2006;39:45-48.
16. Fear C, Sharp H, Healy D: Obsessive-compulsive disorder with delusions. Psychopathology 2000;33:55-61.
17. Catapano F, Sperandeo R, Perris F, Lanzaro M, Maj M: Insight and resistance in patients with obsessive-compulsive disorder. Psychopathology 2001;34:62-68.
18. Lykouras L, Alevizos B, Michalopoulou P, Rabavilas A: Obsessive-compulsive symptoms induced by atypical antipsychotics: a review of the reported cases. Progr Neuropsychopharmacol Biol Psychiatry 2003;27:333-346.
19. Poyurovsky M, Fuchs C, Faragian S, Kriss V, Weisman G, Pashinian A, et al: Preferential aggregation of obsessive-compulsive spectrum disorders in schizophrenia patients with obsessive-compulsive disorder. Can J Psychiatry 2006;51:746-754.
20. Reznik I, Mester R, Kotler M, Weizman A: Obsessive-compulsive schizophrenia: a new diagnostic entity? J Neuropsychiatry Clin Neurosci 2001;13:115-116.
21. Reznik I, Kotler M, Weizman A: Obsessive and compulsive symptoms in schizophrenia patients - from neuropsychology to clinical typology and classification. J Neuropsychiatry Clin Neurosci 2005;17:254-255.
22. Whitney KA, Fastenau PS, Evans JD, Lysaker PH: Comparative neuropsychological function in obsessive-compulsive disorder and schizophrenia with and without obsessive-compulsive symptoms. Schizophr Res 2004;69:75-83.
23. Fenton WS, McGlashan TH: Long-term outcome of obsessive-compulsive disorder with psychotic features. J Nerv Ment Dis 1990;178:760-761.
24. Lysaker PH, Whitney KA, Davis LW: Obsessive-compulsive and negative symptoms in schizophrenia: associations with coping preference and hope. Psychiatry Res 2006;141:253-259.
25. Lysaker PH, Lancaster RS, Nees MA, Davis LW: Patterns of obsessive-compulsive symptoms and social function in schizophrenia. Psychiatry Res 2004;125:139-146.
26. Hwang MY, Morgan JE, Losconzcy MF: Clinical and neuropsychological profiles of obsessive-compulsive schizophrenia: a pilot study. J Neuropsychiatry Clin Neurosci 2000;12:91-94.
27. Friedlander L, Desrocher M: Neuroimaging studies of obsessive-compulsive disorder in adults and children. Clin Psychol Rev 2006;26:32-49.
28. Chamberlain SR, Blackwell AD, Fineberg NA, Robbins TW, Sahakian BJ: The neuropsychology of obsessive-compulsive disorder: the importance of failures in cognitive and behavioural inhibition as candidate endophenotypic markers. Neurosci Biobehav Rev 2005;29:399-419.
29. Hoff AL, Kremen WS: Neuropsychology in schizophrenia: an update. Curr Opin Psychiatry 2003;16:149-155.
30. Keshavan MS, Berger G, Zipursky RB, Wood SJ, Pantelis C: Neurobiology of early psychosis. Br J Psychiatry Suppl 2005;48:S8-S18.
31. Whiteside SP, Port JD, Abramowitz JS: A meta-analysis of functional neuroimaging in obsessive-compulsive disorder. Psychiatry Res 2004;132:69-79.
32. Van den Heuvel OA, Veltman DJ, Groenewegen HJ, Cath DC, van Balkom AJ, van Hartskamp J, et al: Frontal-striatal dysfunction during planning in obsessive-compulsive disorder. Arch Gen Psychiatry 2005;62:301-309.
33. Rasser PE, Johnston P, Lagopoulos J, Ward PB, Schall U, Thienel R, et al: Functional MRI BOLD response to Tower of London performance of first-episode schizophrenia patients using cortical pattern matching. Neuroimage 2005;26:941-951.
34. Wagner G, Koch K, Reichenbach JR, Sauer H, Schlosser RG: The special involvement of the rostrolateral prefrontal cortex in planning abilities: an event-related fMRI study with the Tower of London paradigm. Neuropsychologia 2006;44:2337-2347.
35. Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF: A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry 2006;11:622-632.
36. Li X, May RS, Tolbert LC, Jackson WT, Flournoy JM, Baxter LR: Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study. J Clin Psychiatry 2005;66:736-743.
37. Meyer JM, Simpson GM: From chlorpromazine to olanzapine: a brief history of antipsychotics. Psychiatr Serv 1997;48:1137-1139.
38. Yang SH, McNeely MJ: Rhabdomyolysis, pancreatitis, and hyperglycemia with ziprasidone. Am J Psychiatry 2002;159:1435.
39. El Mansari M, Blier P: Mechanisms of action of current and potential pharmacotherapies of obsessive-compulsive disorder (review). Progr Neuropsychopharmacol Biol Psychiatry 2006;30:362-373.
40. Maina G, Albert U, Salvi V, Bogetto F: Weight gain during long-term treatment of obsessive-compulsive disorder: a prospective comparison between serotonin reuptake inhibitors. J Clin Psychiatry 2004;65:1365-1371.
41. Braconnier A, Le Coent R, Cohen D; DEROXADO Study Group: Paroxetine versus clomipramine in adolescents with severe major depression: a double-blind, randomized, multicenter trial. J Am Acad Child Adolesc Psychiatry 2003;42:22-29.
42. Pigott TA, Seay SM: A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. J Clin Psychiatry 1999;60:101-106.
43. Meltzer HY, Li Z, Kaneda Y, Ichikawa J: Serotonin receptors: their key role in drugs to treat schizophrenia. Progr Neuropsychopharmacol Biol Psychiatry 2003;27:1159-1172.
44. Meltzer HY: Role of serotonin in the action of atypical antipsychotic drugs. Clin Neurosci 1995;3:64-75.
45. Steingard S, Chengappa KNR, Baker R, Schooler NR: Clozapine, obsessive symptoms, and serotonergic mechanisms. Am J Psychiatry 1993;150:1435.
46. Mahendran R, Liew E, Subramaniam M: De novo emergence of obsessive-compulsive symptoms with atypical antipsychotics in Asian patients with schizophrenia or schizoaffective disorder: a retrospective, cross-sectional study. J Clin Psychiatry 2007;68:542-545.
47. Reznik I, Yavin I, Stryjer R, Spivak B, Gonen N, Strous R, et al: Clozapine in the treatment of obsessive-compulsive symptoms in schizophrenia patients: a case series study. Pharmacopsychiatry 2004;37:52-56.
48. Lin SK, Su SF, Pan CH: Higher plasma drug concentration in clozapine-treated schizophrenic patients with side effects of obsessive/compulsive symptoms. Ther Drug Monit 2006;28:303-307.
49. Alevizos B, Lykouras L, Zervas IM, Christodoulou GN: Risperidone-induced obsessive-compulsive symptoms: a series of six cases. J Clin Psychopharmacol 2002;22:461-467.
50. Alevizos B, Lykouras L, Zervas IM, Christodoulou GN: Reply to 'Risperidone-induced obsessive-compulsive symptoms: serotonin-dopamine imbalance?' J Clin Psychopharmacol 2004;24:549.
51. Ozer S, Arsava M, Erturul A, Demir B: Obsessive-compulsive symptoms associated with quetiapine treatment in a schizophrenic patient: a case report. Progr Neuropsychopharmacol Biol Psychiatry 2006;30:724-727.
52. Stamouli S, Lykouras L: Quetiapine-induced obsessive-compulsive symptoms: a series of five cases. J Clin Psychopharmacol 2006;26:396-400.
53. Alevizos B, Papageorgiou C, Christodoulou GN: Obsessive-compulsive symptoms with olanzapine. Int J Neuropsychopharmacol 2004;7:375-377.
54. Carlsson ML, Carlsson A, Nilsson M: Schizophrenia: from dopamine to glutamate and back. Curr Med Chem 2004;11:267-277.
55. Henderson DC, Kunkel L, Nguyen DD, Borba CP, Daley TB, Louie PM, et al: An exploratory open label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. Acta Psychiatr Scand 2006;113:142-147.
56. Connor KM, Payne VM, Gadde KM, Zhang W, Davidson JR: The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients. J Clin Psychiatry 2005;66:49-51.
57. Rocha FL, Hara C: Benefits of combining aripiprazole to clozapine: three case reports. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:1167-1169.
58. Zink M, Knopf U, Kuwilsky A: Management of clozapine-induced obsessive-compulsive symptoms in a man with schizophrenia. Aust NZ J Psychiatry 2006;41:293-294.
59. Hosàk L: Role of the COMT gene Val158Met polymorphism in mental disorders: a review. Eur Psychiatry 2007;22:276-281.
60. Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, Straub RE, et al: Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA 2001;98:6917-6922.
61. Meyer-Lindenberg A, Kohn PD, Kolachana B, Kippenhan S, Inerney-Leo A, Nussbaum R, et al: Midbrain dopamine and prefrontal function in humans: interaction and modulation by COMT genotype. Nat Neurosci 2005;8:594-596.
62. Weinberger DR, Egan MF, Bertolino A, Callicott JH, Mattay VS, Lipska BK, et al: Prefrontal neurons and the genetics of schizophrenia. Biol Psychiatry 2001;50:825-844.
63. Poyurovsky M, Michaelovsky E, Frisch A, Knoll G, Amir I, Finkel B, et al: COMT Val158Met polymorphism in schizophrenia with obsessive-compulsive disorder: a case-control study. Neurosci Lett 2005;389:21-24.
64. Gothelf D, Michaelovsky E, Frisch A, Zohar AH, Presburger G, Burg M, et al: Association of the low-activity COMT 158Met allele with ADHD and OCD in subjects with velocardiofacial syndrome. Int J Neuropsychopharmacol 2007;10:301-308.
65. Lochner C, Kinnear CJ, Hemmings SM, Seller C, Niehaus DJ, Knowles JA, et al: Hoarding in obsessive-compulsive disorder: clinical and genetic correlates. J Clin Psychiatry 2005;66:1155-1160.
66. Smolka MN, Schumann G, Wrase J, Grusser SM, Flor H, Mann K, et al: Catechol-O-methyltransferase val158met genotype affects processing of emotional stimuli in the amygdala and prefrontal cortex. J Neurosci 2005;25:836-842.
67. Bertolino A, Rubino V, Sambataro F, Blasi G, Latorre V, Fazio L, et al: Prefrontal-hippocampal coupling during memory processing is modulated by COMT val158met genotype. Biol Psychiatry 2006;60:1250-1258.
68. Azzam A, Mathews CA: Meta-analysis of the association between the catecholamine-O-methyl-transferase gene and obsessive-compulsive disorder. Am J Med Genet B Neuropsychiatr Genet 2003;123:64-69.
69. Meyer-Lindenberg A, Buckholtz JW, Kolachana B, Hariri R, Pezawas L, Blasi G, et al: Neural mechanisms of genetic risk for impulsivity and violence in humans. Proc Natl Acad Sci USA 2006;103:6269-6274.
70. Henn FA: The NMDA receptor as a site for pathogenesis. Arch Gen Psychiatry 1995;52:1008-1010.
71. Konradi C, Heckers S: Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment. Pharmacol Ther 2003;97:153-179.
72. Roberto M, Scuri R, Brunelli M: Differential effects of PACAP-38 on synaptic responses in rat hippocampal CA1 region. Learn Mem 2001;8:265-271.
73. Farber NB: The NMDA receptor hypofunction model of psychosis. Ann NY Acad Sci 2003;1003:119-130.
74. Marino MJ, Conn PJ: Direct and indirect modulation of the N-methyl D-aspartate receptor. Curr Drug Targets CNS Neurol Disord 2002;1:1-16.
75. Zink M: Augmentation of olanzapine in treatment-resistant schizophrenia. J Psychiatry Neurosci 2005;30:409-415.
76. Tsai G, Ralph-Williams RJ, Martina M, Bergeron R, Berger-Sweeney J, Dunham KS, et al: Gene knockout of glycine transporter 1: characterization of the behavioral phenotype. Proc Natl Acad Sci USA 2004;101:8485-8490.
77. Sur C, Kinney GG: The therapeutic potential of glycine transporter-1 inhibitors. Expert Opin Investig Drugs 2004;13:515-521.
78. Whiteside SP, Port JD, Deacon BJ, Abramowitz JS: A magnetic resonance spectroscopy investigation of obsessive-compulsive disorder and anxiety. Psychiatry Res 2006;146:137-147.
79. Pittenger C, Krystal JH, Coric V: Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRX 2006;3:69-81.
80. Poyurovsky M, Weizman R, Weizman A, Koran L: Memantine for treatment-resistant OCD. Am J Psychiatry 2005;162:2191-2192.
81. Coric V, Taskiran S, Pittenger C, Wasylink S, Mathalon DH, Valentine G, et al: Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry 2005;58:424-428.
82. Lafleur DL, Pittenger C, Kelmendi B, Gardner T, Wasylink S, Malison RT, et al: N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Psychopharmacology 2006;184:254-256.
83. Henn FA, Edwards E, Anderson D, Vollmayr B: Psychotherapy and antidepressant treatment of depression: evidence for similar neurobiological mechanisms. World Psychiatry 2002;1:115-117.
84. Joel D: Current animal models of obsessive compulsive disorder: a critical review. Progr Neuropsychopharmacol Biol Psychiatry 2006;30:374-388.